雲頂新耀宣佈中國國家藥品監督管理局正式受理伊曲莫德（VELSIPITY(R)）
Dec 17, 2024 10:53 HKT |  |
|
云顶新耀宣布中国国家药品监督管理局正式受理伊曲莫德（VELSIPITY(R)）
Dec 17, 2024 10:47 HKT | |
|
Fosun Bolsters Core Business with Two Key Asset Privatizations
Dec 13, 2024 11:25 HKT | |
|
连续私有化两家核心企业 复星深化主业布局
Dec 13, 2024 11:22 HKT | |
|
連續私有化兩家核心企業 復星深化主業佈局
Dec 13, 2024 11:17 HKT | |
|
Everest Medicines Announces the First Prescription of VELSIPITY(R) Issued in Macau
Dec 12, 2024 12:11 HKT | |
|
雲頂新耀宣佈伊曲莫德（VELSIPITY(R)）在中國澳門的首張處方落地
Dec 12, 2024 12:02 HKT | |
|
云顶新耀宣布伊曲莫德（VELSIPITY(R)）在中国澳门的首张处方落地
Dec 12, 2024 11:47 HKT | |
|
Everest Medicines: Accelerating Innovation in Renal Disease to Forge a Path Toward Biopharma Leadership
Dec 11, 2024 11:06 HKT | |
|
雲頂新耀：加速腎病領域創新 邁向全球生物製藥領先地位
Dec 11, 2024 11:02 HKT | |
|
云顶新耀：加速肾病领域创新 迈向全球生物制药领先地位
Dec 11, 2024 10:56 HKT | |
|
China Medical System: First Prescriptions for Innovative Drug Lumeblue(R) Issued in China
Dec 09, 2024 13:00 HKT |  |
|
Sweetness Affecting Both the Young and Old: Prevent Diabetes with LAC This World Diabetes Day
Dec 04, 2024 14:30 HKT |  |
|
Everest Medicines Announces Positive Results in Preliminary Analysis of Phase 1b/2a Clinical Trial of EVER001, a Novel BTK Inhibitor for the Treatment of Primary Membranous Nephropathy
Dec 04, 2024 11:08 HKT | |
|
雲頂新耀宣佈治療原發性膜性腎病的新型BTK抑制劑EVER001在1b/2a期臨床試驗階段性數據中取得積極結果
Dec 04, 2024 10:59 HKT | |
|
云顶新耀宣布治疗原发性膜性肾病的新型BTK抑制剂EVER001在1b/2a期临床试验阶段性数据中取得积极结果
Dec 04, 2024 10:48 HKT | |
|
China Medical System Gained Exclusive Commercialization Right of Class 1 Innovative Drug Targeting Gout and Hyperuricemia
Dec 02, 2024 21:30 HKT | |
|
康哲藥業獲得治療痛風及高尿酸血症的1類新藥獨家商業化權利
Dec 02, 2024 20:49 HKT | |
|
康哲药业获得治疗痛风及高尿酸血症的1类新药独家商业化权利
Dec 02, 2024 20:37 HKT | |
|
Everest Medicines Announces Acceptance of VELSIPITY New Drug Application in Hong Kong
Dec 02, 2024 10:34 HKT | |
|